10-kHz High-Frequency Spinal Cord Stimulation for Adults With Chronic Noncancer Pain: Health Quality Ontario Recommendation

DRAFT RECOMMENDATION

- Health Quality Ontario, under the guidance of the Ontario Health Technology Advisory Committee, recommends publicly funding spinal cord stimulation at frequencies up to and including 10 kHz in adults with chronic noncancer pain that is refractory to medical management.

RATIONALE FOR THE RECOMMENDATION

The Ontario Health Technology Advisory Committee has reviewed and accepted the findings of the health technology assessment.¹

Ontario Health Technology Advisory Committee members noted that 10-kHz high-frequency spinal cord stimulation appears to reduce pain intensity and pain-related functional disability in carefully selected people with chronic noncancer pain, and that some patients treated with spinal cord stimulation are able to reduce their use of prescription opioids. The committee also recognized that 10-kHz high-frequency spinal cord stimulation does not cause the uncomfortable tingling in the legs that patients may experience with low-frequency (40 Hz to 60 Hz) and moderate-frequency (up to 1.2 kHz) spinal cord stimulation.

Ontario Health Technology Advisory Committee members also recognized the results of the budget impact analysis that suggested there would be cost savings if 10-kHz high-frequency spinal cord stimulation were offered to adults whose symptoms had not been substantially improved with spinal cord stimulation at frequencies up to 1.2 kHz.

Ontario Health Technology Advisory Committee members took into account the lived experience of people living with chronic noncancer pain and people who had experience with spinal cord stimulation therapy. They also considered the 2005 Ontario Health Technology Advisory Committee recommendation on spinal cord stimulation.² Health Quality Ontario agreed that the 2005 recommendation should be expanded to include spinal cord stimulation at frequencies up to 10 kHz.
# Decision Determinants for 10-kHz High-Frequency Spinal Cord Stimulation for Adults With Chronic Noncancer Pain

<table>
<thead>
<tr>
<th>Decision Criteria</th>
<th>Subcriteria</th>
<th>Decision Determinants Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall clinical benefit</td>
<td>Effectiveness</td>
<td>10-kHz high-frequency spinal cord stimulation (SCS) reduces pain intensity (GRADE: Moderate), decreases functional disability (GRADE: Moderate), decreases opioid use (GRADE: Low), and improves quality of life (GRADE: Moderate).</td>
</tr>
<tr>
<td></td>
<td>Safety</td>
<td>There is no increased risk of adverse events with 10-kHz high-frequency SCS compared with SCS at frequencies up to 1.2 kHz.</td>
</tr>
<tr>
<td></td>
<td>Burden of illness</td>
<td>The estimated prevalence of chronic pain in Canadian adults ranges from 11% to 44%. The psychosocial morbidity, physical functional disability, and sleep impairment related to chronic pain represent a heavy burden for patients, making it a costly disease for patients, families, employers, and the health care system.</td>
</tr>
<tr>
<td></td>
<td>Need</td>
<td>Spinal cord stimulation at frequencies up to 1.2 kHz is available in Ontario through existing programs. However, no other treatments are available when it or other pain management options fail.</td>
</tr>
<tr>
<td>Consistency with patient values and with expected societal and ethical values</td>
<td>Patient values</td>
<td>Participants reported that currently available SCS reduced their pain. They felt it improved their quality of life and their ability to carry out activities of daily living.</td>
</tr>
<tr>
<td></td>
<td>Societal values</td>
<td>Participants reported feeling that currently available SCS improved their overall health and reduced their pain, and 10-kHz high-frequency SCS may reduce the tingling sensation associated with conventional SCS. Adopting a treatment that is effective and cost-saving is likely congruent with societal values to use public resources efficiently.</td>
</tr>
<tr>
<td></td>
<td>Ethical values</td>
<td>Adoption of 10-kHz high-frequency SCS is likely to be congruent with expected ethical values of beneficence or doing good.</td>
</tr>
<tr>
<td>Cost-effectiveness</td>
<td>Economic evaluation</td>
<td>There was limited evidence about the effectiveness of 10-kHz high-frequency SCS in people who had first tried SCS at frequencies up to 1.2 kHz. Therefore, we could not develop an economic evaluation of this pathway of care (SCS at frequencies up to 1.2 kHz followed by 10-kHz high-frequency SCS), and we could not estimate the cost-effectiveness of this health technology for Ontario.</td>
</tr>
</tbody>
</table>
### Decision Criteria

<table>
<thead>
<tr>
<th>Decision Criteria</th>
<th>Subcriteria</th>
<th>Decision Determinants Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feasibility of adoption into health system</td>
<td>Economic feasibility</td>
<td>We estimated that the average annual cost of SCS therapy with a new wireless system was approximately $34,660, including a device cost of approximately $22,350. We estimated that the average annual cost of SCS therapy with currently available (wired) devices was approximately $47,860 (including the costs of the procedure, complications, and device). Using 10-kHz high-frequency SCS with a new wireless device to treat adults with chronic noncancer pain in whom currently available SCS therapies have not been effective may result in cost savings of about $0.1 million to $0.2 million per year over the next 5 years, for a potential total 5-year net cost savings of about $0.73 million.</td>
</tr>
<tr>
<td></td>
<td>Organizationally feasibility</td>
<td>Ontario has existing SCS programs, and 10-kHz high-frequency SCS can be integrated into these programs.</td>
</tr>
</tbody>
</table>

- **Feasibility of adoption into health system**
  - How feasible is it to adopt the health technology/intervention into the Ontario health care system?
- **Economic feasibility**
  - How economically feasible is the health technology/intervention?

**Abbreviation:** GRADE, Grading of Recommendations Assessment, Development, Evaluation; SCS, spinal cord stimulation.

*The anticipated or assumed common patient, societal, and ethical values held in regard to the target condition, target population, and/or treatment options. Unless there is evidence from scientific sources to corroborate the true nature of the patient, societal, and ethical values, the expected values are considered.*
REFERENCE

(1) TBA


Disclaimer

About Health Quality Ontario

About the Ontario Health Technology Advisory Committee

How to Obtain Recommendation Reports From Health Quality Ontario

Health Quality Ontario
130 Bloor Street West, 10th Floor
Toronto, Ontario
M5S 1N5
Tel: 416-323-6868
Toll Free: 1-866-623-6868
Fax: 416-323-9261
Email: EvidenceInfo@hqontario.ca
www.hqontario.ca

ISBN TBA (PDF)

© Queen’s Printer for Ontario, 2019

Citation

TBA